<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of atypical and malignant (WHO grade 2 and 3) meningioma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of atypical and malignant (WHO grade 2 and 3) meningioma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of atypical and malignant (WHO grade 2 and 3) meningioma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen A Shih, MD, MS, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John K Park, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H444764622">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Meningiomas account for approximately one-third of primary central nervous system tumors (
         <a class="graphic graphic_table graphicRef81566" href="/z/d/graphic/81566.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef72275" href="/z/d/graphic/72275.html" rel="external">
          figure 1
         </a>
         ). Most meningiomas are benign (World Health Organization [WHO] grade 1), although up to one-fourth of such tumors are classified as atypical (WHO grade 2) or malignant (WHO grade 3). (See
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
         The management of patients with meningioma requires a balance between definitive treatment of the tumor and avoidance of neurologic damage from the treatment. Patient-specific factors (eg, presence or absence of symptoms, age, comorbidity), the location of the meningioma in relation to critical brain structures and regions, and the histopathologic characteristics (WHO grade) of the meningioma are all important factors in determining the optimal treatment.
        </p>
        <p>
         The management of WHO grade 2 and grade 3 meningiomas will be reviewed here. Other topics on meningioma include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epidemiology, pathology, clinical features, and diagnosis of meningioma (see
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of benign meningiomas (see
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic treatment for recurrent meningioma (see
         <a class="medical medical_review" href="/z/d/html/15693.html" rel="external">
          "Systemic treatment of recurrent meningioma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H444764636">
         <span class="h1">
          PREOPERATIVE EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of meningioma is generally suspected on the basis of characteristic imaging findings and is then confirmed by histopathology, obtained at the time of surgical resection. (See
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         Differentiating an atypical or malignant meningioma from a benign meningioma purely on the basis of neuroimaging is difficult. While the presence of one or more atypical imaging features may suggest high-grade histology, none of these neuroimaging findings are sufficiently specific to be clinically useful. (See
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Neuroimaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H444764643">
         <span class="h1">
          SURGICAL RESECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complete surgical resection is preferred when a meningioma is in an accessible location, since complete resection of the tumor and its dural attachment can be curative, and extent of resection is consistently identified as an independent prognostic factor for both progression-free and overall survival [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Multiple advances in neurosurgery, including microsurgery, neuroendoscopy, improved preoperative imaging, and intraoperative image-guided approaches, have extended the neurosurgeon's ability to resect lesions that were previously considered only partially resectable or unresectable, while minimizing damage to normal brain. The goals of surgery, the classification of the extent of surgical resection, surgical morbidity, and the perioperative medical management for all patients with meningioma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma", section on 'Extent of resection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H537373725">
         <span class="h1">
          ADJUVANT RADIATION THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complete surgical resection is sometimes difficult to achieve for malignant and atypical meningiomas, and partially resected tumors have a high rate of local recurrence as well as increased disease-specific mortality [
         <a href="#rid3">
          3,4
         </a>
         ]. Adjuvant radiation therapy (RT) is a standard component of initial therapy in patients with malignant meningiomas and subtotally resected atypical meningiomas in an effort to improve local control [
         <a href="#rid2">
          2
         </a>
         ]. For patients with atypical meningioma who undergo apparent gross total resection, the role of adjuvant radiation is less clear, as discussed below. (See
         <a class="local">
          'Atypical meningioma'
         </a>
         below.)
        </p>
        <p>
         Newer RT techniques that have been used in small series include stereotactic radiosurgery (SRS) [
         <a href="#rid5">
          5-7
         </a>
         ], hypofractionated stereotactic RT [
         <a href="#rid8">
          8,9
         </a>
         ], and particle irradiation (proton beam, carbon ion) [
         <a href="#rid10">
          10,11
         </a>
         ]. No single approach has been shown to be superior to others, but they all reflect advances in conformal techniques. Selection of a specific modality is often limited by technical considerations; as an example, a tumor must be adequately small to be safely eligible for SRS. The delivery of RT for meningiomas using various techniques is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma", section on 'Radiation therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2177501">
         <span class="h2">
          Malignant meningioma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignant meningiomas are locally aggressive neoplasms with a very high rate of recurrence or progression, even after apparent complete resection. Adjuvant RT is a standard component of initial management for all malignant meningiomas, regardless of the extent of resection, in an attempt to improve local control and overall survival.
        </p>
        <p>
         The natural history of malignant meningiomas and support for the use of adjuvant RT are derived from observational studies, most of which are small, single-center retrospective analyses with heterogeneous pathologic inclusion criteria and treatment approaches [
         <a href="#rid12">
          12-17
         </a>
         ]. Within these limitations, the data suggest that malignant meningiomas are associated with a recurrence rate of approximately 60 to 90 percent by five years after surgery and a five-year overall survival of 20 to 50 percent. Adjuvant RT appears to decrease the recurrence rate by approximately half and may improve five-year survival to greater than 50 percent [
         <a href="#rid15">
          15,18
         </a>
         ].
        </p>
        <p>
         The optimal dose of RT for malignant meningioma is not well established, and several studies have suggested that a dose of greater than 60 Gy is necessary to achieve durable local control [
         <a href="#rid10">
          10,12,13,19
         </a>
         ]. We generally suggest a dose of 60 Gy when treating malignant meningiomas, based on the maximal safe dose deliverable to the surrounding normal brain. Even at this dose, local failures are common, however, suggesting that further investigation into safe dose escalation techniques and other novel strategies is needed to optimize outcomes [
         <a href="#rid10">
          10,19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H537373553">
         <span class="h2">
          Atypical meningioma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical meningiomas are associated with an intermediate recurrence rate compared with benign and malignant meningiomas, and in some cases, particularly with progressive or multiply recurrent tumors, overall survival is shortened.
        </p>
        <p class="headingAnchor" id="H1443726395">
         <span class="h3">
          Incompletely resected tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who undergo incomplete resection or biopsy of an atypical meningioma, the rate of recurrence or progression ranges from 60 to 100 percent [
         <a href="#rid21">
          21,22
         </a>
         ]. Adjuvant RT improves local control, aims to prevent further neurologic morbidity related to growth of the residual tumor, and may improve survival [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         Accurate delineation of the residual tumor following surgery using contemporary imaging studies is critical for optimal results with postoperative RT [
         <a href="#rid25">
          25
         </a>
         ]. Absent prospective randomized trials, doses of 54 to 60 Gy are typically used when treating atypical meningiomas [
         <a href="#rid21">
          21,26,27
         </a>
         ]. Even with a target dose of 60 Gy, however, disease progression commonly occurs [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         For small tumors amenable to stereotactic radiotherapy, this technique can be used to maximize radiation conformality. SRS is sometimes used to treat small tumors; however, there may be a higher risk of local failure at the margins, and further studies with long-term follow-up are needed [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2172974046">
         <span class="h3">
          Completely resected tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who undergo apparent complete resection of an atypical meningioma, the role of adjuvant RT is debated. Although multicenter trials are ongoing, there are no randomized data yet available to guide decision-making in these patients, and practice varies across centers. The potential benefits of adjuvant RT in terms of preventing or delaying tumor recurrence are more closely balanced with the risks and side effects of RT, and it is particularly important to assess individual patient preferences and tolerance for risk, which may vary when presented with similar information.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Our approach
         </strong>
         – Based on the available data and clinical experience, for most patients who undergo gross total resection of an atypical meningioma and are at low risk for complications of RT, we suggest adjuvant RT. The goal of RT is to maximize local tumor control and prevent neurologic morbidity associated with tumor recurrence. For patients with an increased risk for complications of RT, we suggest observation with close follow-up and imaging surveillance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of recurrence
         </strong>
         – The estimated recurrence rate after imaging-confirmed gross total resection in patients not treated with adjuvant RT is approximately 30 to 50 percent at a median of five years or less, with rates of failure trending higher with longer follow-up [
         <a href="#rid26">
          26,29-31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Certain defining histopathologic features may be associated with a higher risk of recurrence than others, although this has not been well defined. Individual pathologic features that have been reported to independently increase risk for recurrence after gross total resection of an atypical meningioma include the presence of brain invasion [
         <a href="#rid32">
          32
         </a>
         ], a high number of mitoses per 10 high-powered fields (eg, closer to 20 than 4) [
         <a href="#rid16">
          16,33-35
         </a>
         ], and prominent nucleoli [
         <a href="#rid26">
          26
         </a>
         ]. Molecular genetic risk stratification is also being studied. Clinical risk factors reported in one or more studies include older age, nonconvexity tumor location, and less than Simpson grade I resection [
         <a href="#rid17">
          17,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Molecular risk stratification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma", section on 'Extent of resection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy of adjuvant RT
         </strong>
         – Most but not all observational studies suggest that adjuvant RT improves local control and progression-free survival after complete resection of an atypical meningioma [
         <a href="#rid22">
          22,23,26,31,36-39
         </a>
         ]. The impact of RT on overall survival is less clear, however, and most studies have included insufficient numbers of patients or length of follow-up to adequately assess this outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Examples of observational studies that support the use of adjuvant RT in the management of completely resected atypical meningiomas including the following [
         <a href="#rid21">
          21,26,31,39-42
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the intermediate-risk group of the prospective Radiation Therapy Oncology Group (RTOG) 0539 trial, 52 patients with completely resected, newly diagnosed atypical meningioma (n = 36) or recurrent grade 1 meningioma (n = 16) were enrolled prospectively; all received RT (54 Gy in 30 fractions) [
         <a href="#rid40">
          40
         </a>
         ]. Three-year progression-free survival was 94 percent, which was improved compared with an expected rate of 70 percent based on historical controls. There were no serious (grade 3 or 4) treatment-related adverse events. Further follow-up is ongoing, which may help better define whether the dose of RT used in the trial (54 Gy) was sufficient to maintain long-term local control. Very similar three-year progression-free survival (89 percent) was reported in the prospective arm of the European Organisation for Research and Treatment of Cancer (EORTC) 22042-26042 study that included 56 patients with completely resected atypical meningiomas who received a higher dose of postoperative RT (60 Gy in 30 fractions) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective, single-institution cohort study of 230 patients with atypical meningioma who underwent complete or partial resection, 51 patients (22 percent) received immediate postoperative adjuvant RT (most commonly 59.4 Gy in 33 fractions) [
         <a href="#rid39">
          39
         </a>
         ]. Compared with surveillance, RT was associated with substantially lower risk of progression/recurrence (hazard ratio [HR] 0.21, 95% CI 0.11-0.41). Among patients who underwent gross total resection (n = 151; 18 patients received early RT), early RT was associated with improved progression-free survival compared with surveillance at both 5 years (94 versus 70 percent) and 10 years (94 versus 63 percent). Disease-specific survival for the entire cohort was very high (96 percent), and RT was not associated with differences in overall survival with a median follow-up of nearly seven years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to these series, several population-based studies using cancer data registries have examined survival outcomes after gross total resection of atypical meningiomas [
         <a href="#rid1">
          1,43-45
         </a>
         ]. In the largest of these, which included over 7800 atypical meningioma cases, five-year overall survival rates for grade 1, 2, and 3 meningioma were 86, 76, and 55 percent, respectively. In a multivariable analysis that included 3529 atypical meningiomas for which complete details on extent of resection and postoperative RT were available, both gross total resection (HR 0.70, 95% CI 0.55-0.89) and adjuvant RT (HR 0.70, 95% CI 0.53-0.92) were associated with improved overall survival. Among patients who underwent gross total resection, five-year overall survival rates with and without adjuvant RT were 88 and 79 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks of adjuvant RT
         </strong>
         – The potential benefits of RT are weighed against the short- and long-term side effects and risks of RT. Factors that increase the risk of side effects or delayed toxicities of RT include advanced age, low functional status, large treatment volume, and proximity of the radiation field to critical structures such as the optic pathways or pituitary gland. (See
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma", section on 'Quality of life'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H444764650">
         <span class="h2">
          Ongoing protocols
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several ongoing or completed prospective cooperative group protocols are studying the role of RT in the management of patients with WHO grade 2 or 3 meningioma:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EORTC 22042-26042 (NCT00626730) – In a phase II study run by the EORTC, patients with atypical or malignant meningioma were treated with adjuvant RT following surgical resection [
         <a href="#rid46">
          46
         </a>
         ]. A dose of 60 Gy was used for newly diagnosed patients with atypical or anaplastic meningioma following a gross total resection, and a dose of 70 Gy was used for subtotally resected tumors (Simpson grades 3 and 4). Initial results of the completely resected atypical meningioma cohort has been published. (See
         <a class="local">
          'Completely resected tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NRG BN-003 (NCT03180268) and the ROAM (Radiation versus Observation following resection of Atypical Meningioma) trial – NRG BN-003 and ROAM are multicenter cooperative trials in which patients are randomly assigned to RT or observation after gross total resection of an atypical meningioma.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H446744">
         <span class="h1">
          SURVEILLANCE AFTER INITIAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cranial imaging (preferably magnetic resonance imaging [MRI]) is used following initial treatment to monitor for evidence of recurrence or progression of residual disease. There are no prospective studies that define the optimal schedule for such imaging. In general, patients with malignant meningioma require closer radiology surveillance than patients with atypical meningioma.
        </p>
        <p>
         An approach that is consistent with the National Comprehensive Cancer Network (NCCN) includes the following [
         <a href="#rid47">
          47
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with atypical meningioma, we typically obtain an MRI at 3, 6, and 12 months postoperatively, then every 6 to 12 months for five years, then every one to three years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with malignant meningioma, we typically obtain MRIs every three to six months for three to five years after initial therapy, then every 6 to 12 months.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H444764685">
         <span class="h1">
          RECURRENT DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most recurrences of meningioma are local or adjacent to a radiation treatment field. Although the majority occur within the first two to three years after resection, late recurrences are not uncommon.
        </p>
        <p>
         Metastases of cranial meningiomas to the spinal cord due to spreading through the cerebrospinal fluid are rare and are more frequently associated with atypical or malignant meningiomas [
         <a href="#rid48">
          48,49
         </a>
         ]. Extracranial metastases to sites such as bone, lungs, and liver are rare but do occur, more commonly in association with malignant tumors; the rate of distant spread has been reported to be as high as 10 percent in retrospective series [
         <a href="#rid12">
          12,16,33,50,51
         </a>
         ].
        </p>
        <p>
         Risk factors for recurrent disease after surgery and RT include grade 3 histology, brain and/or bone involvement, and elevated proliferation index [
         <a href="#rid52">
          52
         </a>
         ]. Certain molecular genetic alterations may also predict worse biologic behavior. (See
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Molecular risk stratification'
         </a>
         .)
        </p>
        <p>
         For patients who recur locally after their initial treatment, additional surgery and/or radiation therapy (RT) can sometimes provide effective therapy, and occasionally permit long-term overall and recurrence-free survival. However, several series indicate that recurrent atypical meningiomas have a high rate of treatment failure and survival outcomes that are similar to or worse than those of malignant meningioma [
         <a href="#rid18">
          18,53,54
         </a>
         ]. In the high-risk arm of the Radiation Therapy Oncology Group (RTOG) 0539 phase II study, five-year progression-free and overall survival with radiation for recurrent atypical meningioma were 30 and 48 percent, respectively [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         The principles underlying the use of surgery or radiation are similar to those for patients presenting de novo, but appropriate management requires a consideration of the effects of prior surgery and/or RT. (See
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma"
         </a>
         .)
        </p>
        <p>
         Systemic therapy for recurrent disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15693.html" rel="external">
          "Systemic treatment of recurrent meningioma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2177445">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical and malignant meningiomas are associated with an increased risk of local recurrence and decreased overall survival compared with grade 1 meningiomas.
        </p>
        <p>
         Population-based survival estimates from the Surveillance, Epidemiology, and End Results (SEER) registry in the United States are available for atypical meningiomas diagnosed between 2004 and 2018, spanning several modifications to the WHO classification schema for meningioma grading. Among 4476 atypical meningiomas, 1-, 5-, and 10-year survival rates were 92, 69, and 34 percent, respectively [
         <a href="#rid55">
          55
         </a>
         ]. Patients with malignant meningioma have worse outcomes, with five-year overall survival rates of less than 50 percent and median survival ranging from 42 to 50 months [
         <a href="#rid56">
          56-58
         </a>
         ].
        </p>
        <p>
         Aside from histopathologic grade, the most commonly reported risks factors for worse outcome are subtotal resection, large tumor size, and nonconvexity tumor location (including infratentorial tumors) [
         <a href="#rid44">
          44,55,57,59
         </a>
         ]. Age has been inconsistently associated with outcome and may have a bimodal effect, with worse outcomes at both extremes of the age distribution. As with benign meningiomas, the quality of life of patients with atypical and malignant meningiomas can be impacted by short- and long-term consequences of the tumor itself, surgery, and radiation therapy (RT). (See
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma", section on 'Quality of life'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1793316308">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">
          "Society guideline links: Primary brain tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H444764692">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical resection
         </strong>
         – Complete surgical resection is the preferred initial approach when a meningioma is in an accessible location, since complete resection of the tumor and its dural attachment can be curative. Atypical (grade 2) and malignant (grade 3) meningiomas are associated with a significantly increased risk for recurrence even after apparent complete resection. (See
         <a class="local">
          'Adjuvant radiation therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjuvant radiation therapy
         </strong>
         – The role of adjuvant radiation therapy (RT) varies according to the grade of the tumor and the extent of resection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Malignant (grade 3) meningioma
         </strong>
         – For patients with malignant meningioma, we recommend adjuvant RT, regardless of the extent of surgery (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Malignant meningioma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Atypical (grade 2) meningioma, incomplete resection
         </strong>
         – For patients with atypical meningioma who have undergone incomplete resection or biopsy, we recommend RT rather than observation after surgery (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Incompletely resected tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Atypical (grade 2) meningioma, gross total resection
         </strong>
         – For patients with atypical meningioma who have undergone gross total resection, the potential benefits of RT are more closely balanced with the risks of side effects and delayed toxicities. Factors that increase the risk of complications from radiation include advanced age, low functional status, large radiation field, and proximity of critical structures. (See
         <a class="local">
          'Completely resected tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who are at low risk for complications of radiation, we suggest adjuvant RT rather than observation after surgery (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Patients who are particularly concerned about radiation toxicity could reasonably choose not to undergo adjuvant radiation, in favor of surveillance by imaging.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who are at increased risk for complications of radiation, we suggest observation rather than adjuvant RT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Patients who want to maximize the chance of avoiding a recurrence and are willing to accept the risk of treatment-related toxicity could reasonably choose adjuvant radiation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance after initial treatment
         </strong>
         – All patients with atypical and malignant meningioma require active surveillance after initial therapy to monitor for recurrence. For patients with atypical meningioma, we obtain MRI at 3, 6, and 12 months postoperatively, then every 6 to 12 months for five years, then every one to three years. Patients with malignant meningioma typically require even more intense follow-up. (See
         <a class="local">
          'Surveillance after initial treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrent disease
         </strong>
         – Most recurrences of meningioma are local or adjacent to a radiation treatment field and can occur within the first two to three years after resection. Additional surgery and/or RT are commonly used to treat recurrent disease. Systemic therapy is as yet ineffective. (See
         <a class="local">
          'Recurrent disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Atypical and malignant meningiomas are associated with an increased risk of local recurrence and decreased overall survival compared with grade 1 meningiomas, and quality of life can be impacted by short- and long-term consequences of the tumor itself, surgery, and RT. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H113903552">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Peter Black, MD, PhD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Aizer AA, Bi WL, Kandola MS, et al. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer 2015; 121:4376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 2021; 23:1821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 2010; 99:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol 2010; 99:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris AE, Lee JY, Omalu B, et al. The effect of radiosurgery during management of aggressive meningiomas. Surg Neurol 2003; 60:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huffmann BC, Reinacher PC, Gilsbach JM. Gamma knife surgery for atypical meningiomas. J Neurosurg 2005; 102 Suppl:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kano H, Takahashi JA, Katsuki T, et al. Stereotactic radiosurgery for atypical and anaplastic meningiomas. J Neurooncol 2007; 84:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girvigian MR, Chen JC, Rahimian J, et al. Comparison of early complications for patients with convexity and parasagittal meningiomas treated with either stereotactic radiosurgery or fractionated stereotactic radiotherapy. Neurosurgery 2008; 62:A19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lominska CE, Unger K, Jean WC, et al. Multisession stereotactic radiosurgery for meningioma results in low rates of post-treatment edema (Available online at http://astro2009.abstractsnet.com/pdfs/2135.pdf accessed June 19, 2012). Int J Radiat Oncol Biol Phys 2009; 75:s242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boskos C, Feuvret L, Noel G, et al. Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys 2009; 75:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Combs SE, Hartmann C, Nikoghosyan A, et al. Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol 2010; 95:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milosevic MF, Frost PJ, Laperriere NJ, et al. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 1996; 34:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dziuk TW, Woo S, Butler EB, et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 1998; 37:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg LA, Prayson RA, Lee J, et al. Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys 2009; 74:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sughrue ME, Sanai N, Shangari G, et al. Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg 2010; 113:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry A, Scheithauer BW, Stafford SL, et al. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999; 85:2046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palma L, Celli P, Franco C, et al. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 1997; 86:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers CL, Won M, Vogelbaum MA, et al. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 2020; 106:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hug EB, Devries A, Thornton AF, et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol 2000; 48:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AW, Bernstein KD, Adams JA, et al. Dose escalation with proton radiation therapy for high-grade meningiomas. Technol Cancer Res Treat 2012; 11:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park H, Kim I, Jung H. Aytpical meningioma: Outcomes and prognostic factors. Int J Radiat Oncol Biol Phys 2009; 75:S238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardesty DA, Wolf AB, Brachman DG, et al. The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. J Neurosurg 2013; 119:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang C, Kaprealian TB, Suh JH, et al. Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma. Neuro Oncol 2017; 19:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unterberger A, Nguyen T, Duong C, et al. Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas. J Neurooncol 2021; 152:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994; 80:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009; 64:56.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (Accessed on March 17, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015; 122:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komotar RJ, Iorgulescu JB, Raper DM, et al. The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg 2012; 117:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adeberg S, Hartmann C, Welzel T, et al. Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 2012; 83:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aizer AA, Arvold ND, Catalano P, et al. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol 2014; 16:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang SY, Park CK, Park SH, et al. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 2008; 79:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquier D, Bijmolt S, Veninga T, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2008; 71:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005; 57:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett OC, Hackney JR, McDonald AM, et al. Pathologic Predictors of Local Recurrence in Atypical Meningiomas Following Gross Total Resection. Int J Radiat Oncol Biol Phys 2019; 103:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park HJ, Kang HC, Kim IH, et al. The role of adjuvant radiotherapy in atypical meningioma. J Neurooncol 2013; 115:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur G, Sayegh ET, Larson A, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol 2014; 16:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mair R, Morris K, Scott I, Carroll TA. Radiotherapy for atypical meningiomas. J Neurosurg 2011; 115:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee G, Lamba N, Niemierko A, et al. Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas. Int J Radiat Oncol Biol Phys 2021; 109:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers L, Zhang P, Vogelbaum MA, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 2018; 129:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber DC, Ares C, Villa S, et al. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol 2018; 128:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bray DP, Quillin JW, Press RH, et al. Adjuvant Radiotherapy Versus Watchful Waiting for World Health Organization Grade II Atypical Meningioma: A Single-Institution Experience. Neurosurgery 2021; 88:E435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy BJ, Davis FG, Freels S, et al. Factors associated with survival in patients with meningioma. J Neurosurg 1998; 88:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rydzewski NR, Lesniak MS, Chandler JP, et al. Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma. Cancer 2018; 124:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown DA, Goyal A, Kerezoudis P, et al. Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry. J Neurooncol 2020; 149:293.
          </a>
         </li>
         <li class="breakAll">
          ClinicalTrials.gov http://www.clinicaltrials.gov/ (Accessed on October 21, 2010).
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and neck cancer. Version 1.2021. Available at: https://www.nccn.org/professionals/physician_gls/ https://www.nccn.org/professionals/physician_gls/ (Accessed on January 29, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang HC, Lee HC, Cho DY. Intracranial malignant meningioma with multiple spinal metastases--a case report and literature review: case report. Spine (Phila Pa 1976) 2006; 31:E1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlain MC, Glantz MJ. Cerebrospinal fluid-disseminated meningioma. Cancer 2005; 103:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavin ML. Metastatic malignant meningioma. J Clin Neuroophthalmol 1989; 9:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueroa BE, Quint DJ, McKeever PE, Chandler WF. Extracranial metastatic meningioma. Br J Radiol 1999; 72:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim D, Niemierko A, Hwang WL, et al. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg 2018; 128:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagshaw HP, Burt LM, Jensen RL, et al. Adjuvant radiotherapy for atypical meningiomas. J Neurosurg 2017; 126:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talacchi A, Muggiolu F, De Carlo A, et al. Recurrent Atypical Meningiomas: Combining Surgery and Radiosurgery in One Effective Multimodal Treatment. World Neurosurg 2016; 87:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Recker MJ, Kuo CC, Prasad D, et al. Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018. J Neurooncol 2022; 160:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Combs SE, Schulz-Ertner D, Debus J, et al. Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. Int J Radiat Oncol Biol Phys 2011; 81:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garzon-Muvdi T, Yang W, Lim M, et al. Atypical and anaplastic meningioma: outcomes in a population based study. J Neurooncol 2017; 133:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maier AD, Bartek J Jr, Eriksson F, et al. Clinical and histopathological predictors of outcome in malignant meningioma. Neurosurg Rev 2020; 43:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stessin AM, Schwartz A, Judanin G, et al. Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis. J Neurosurg 2012; 117:669.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15692 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26308667" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Extent of resection and overall survival for patients with atypical and malignant meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34181733" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : EANO guideline on the diagnosis and management of meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20740303" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Intracranial meningiomas of atypical (WHO grade II) histology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20730473" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A review of malignant meningiomas: diagnosis, characteristics, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14505844" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The effect of radiosurgery during management of aggressive meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15662826" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Gamma knife surgery for atypical meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17361335" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Stereotactic radiosurgery for atypical and anaplastic meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18580776" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Comparison of early complications for patients with convexity and parasagittal meningiomas treated with either stereotactic radiosurgery or fractionated stereotactic radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Multisession stereotactic radiosurgery for meningioma results in low rates of post-treatment edema (Available online at http://astro2009.abstractsnet.com/pdfs/2135.pdf accessed June 19, 2012).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19203844" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189258" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Carbon ion radiation therapy for high-risk meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8598358" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Radiotherapy for atypical or malignant intracranial meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9524097" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19427553" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20225922" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10223247" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9126894" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31786276" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11083080" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22712601" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dose escalation with proton radiation therapy for high-grade meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Aytpical meningioma: Outcomes and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23394332" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28371851" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33635510" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8283256" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19145156" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19145156" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25343186" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22920955" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The role of radiotherapy following gross-total resection of atypical meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22137023" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24891451" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17766430" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18294779" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16145534" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30253235" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pathologic Predictors of Local Recurrence in Atypical Meningiomas Following Gross Total Resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23949108" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The role of adjuvant radiotherapy in atypical meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24696499" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21699480" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Radiotherapy for atypical meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32777336" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28984517" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29960684" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33582821" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Adjuvant Radiotherapy Versus Watchful Waiting for World Health Organization Grade II Atypical Meningioma: A Single-Institution Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9576250" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Factors associated with survival in patients with meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29131312" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32860156" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32860156" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32860156" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17172988" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Intracranial malignant meningioma with multiple spinal metastases--a case report and literature review: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15690330" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cerebrospinal fluid-disseminated meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2522948" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Metastatic malignant meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10505022" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Extracranial metastatic meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28621619" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27611201" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Adjuvant radiotherapy for atypical meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26485411" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Recurrent Atypical Meningiomas: Combining Surgery and Radiosurgery in One Effective Multimodal Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35819682" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20932661" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28429237" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Atypical and anaplastic meningioma: outcomes in a population based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30868425" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinical and histopathological predictors of outcome in malignant meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22900840" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
